Skip to main content
SpringerLink
Log in

Monoclonal Antibodies in Lymphomas

  • Chapter
Book cover Apoptosis, Senescence, and Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1661 Accesses

Summary

Immunotherapy has markedly altered the treatment options available for patients with non-Hodgkin’s lymphoma (NHL). Monoclonal antibodies have revolutionized the treatment of cancers in two respects. First, they represent a therapy with a different mechanism of action than chemotherapy. By providing an alternative type of attack, they may improve outcomes through better efficacy. Second, they represent a major step forward in improving the tolerability of cancer therapies. As a more targeted therapy, monoclonal antibodies enable patients to receive treatment that might not have otherwise been tolerated, potentially extending their lives and decreasing symptomatology. Although each monoclonal antibody was initially developed for one indication, their approvals have enabled exploration of other possible indications. We are only beginning to understand the breadth of diseases, malignant and non-malignant, that might benefit from treatment with these monoclonal antibodies, and how best to use them. Attempts to further improve outcomes in NHL are being explored, including the role of modifications of dose and schedule, chemotherapy combinations, and through the use of other biologics. Monoclonal antibodies represent the epitome of targeted therapy and have the potential to move forward the treatment of lymphomabreak more than any other development since the first use of multiagent chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495–497.

    Article  PubMed  CAS  Google Scholar 

  2. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984, 81:6851–6855.

    Article  PubMed  CAS  Google Scholar 

  3. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643–646.

    Article  PubMed  CAS  Google Scholar 

  4. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522–525.

    Article  PubMed  CAS  Google Scholar 

  5. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999, 231:11–23.

    Article  PubMed  CAS  Google Scholar 

  6. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 2002, 13:593–597.

    Article  PubMed  CAS  Google Scholar 

  7. Kretzschmar T, von Ruden T. Antibody discovery: phage display. Curr Opin Biotechnol 2002, 13:598–602.

    Article  PubMed  CAS  Google Scholar 

  8. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441–449.

    Article  PubMed  CAS  Google Scholar 

  9. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001, 19:3918–3928.

    PubMed  CAS  Google Scholar 

  10. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696–5704.

    Article  PubMed  CAS  Google Scholar 

  11. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981, 67:134–140.

    PubMed  CAS  Google Scholar 

  12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435–445.

    PubMed  CAS  Google Scholar 

  13. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424–1433.

    PubMed  CAS  Google Scholar 

  14. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988, 85:208–212.

    Article  PubMed  CAS  Google Scholar 

  15. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985, 135:973–979.

    PubMed  CAS  Google Scholar 

  16. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994, 15:450–454.

    Article  PubMed  CAS  Google Scholar 

  17. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000, 27:17–24.

    PubMed  CAS  Google Scholar 

  18. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69:584–591.

    PubMed  CAS  Google Scholar 

  19. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O’Brien SM, Keating MJ, Kantarjian HM, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol 2003, 123:850–857.

    Article  PubMed  CAS  Google Scholar 

  20. Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003, 101:2507–2513.

    Article  PubMed  CAS  Google Scholar 

  21. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900–3908.

    PubMed  CAS  Google Scholar 

  22. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949–954.

    Article  PubMed  CAS  Google Scholar 

  23. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, Colomer D, Montserrat E. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001, 98:2771–2777.

    Article  PubMed  CAS  Google Scholar 

  24. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443–446.

    Article  PubMed  CAS  Google Scholar 

  25. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940–3947.

    Article  PubMed  CAS  Google Scholar 

  26. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48:673–683.

    Article  PubMed  CAS  Google Scholar 

  27. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000, 60:7170–7176.

    PubMed  CAS  Google Scholar 

  28. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264–276.

    PubMed  CAS  Google Scholar 

  29. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 2004, 64:7117–7126.

    Article  PubMed  CAS  Google Scholar 

  30. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  31. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-Non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137–5144.

    PubMed  CAS  Google Scholar 

  32. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98:1352–1357.

    Article  PubMed  CAS  Google Scholar 

  33. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002, 59:213–216.

    Article  PubMed  CAS  Google Scholar 

  34. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101:466–468.

    Article  PubMed  CAS  Google Scholar 

  35. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754–758.

    Article  PubMed  CAS  Google Scholar 

  36. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997, 90:2188–2195.

    PubMed  CAS  Google Scholar 

  37. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  38. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1103–1108.

    Article  PubMed  CAS  Google Scholar 

  39. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135–3143.

    PubMed  CAS  Google Scholar 

  40. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999, 10: 655–661.

    Article  PubMed  CAS  Google Scholar 

  41. Hainsworth JD, Litchy S, Burris HA, III, Scullin DC, Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:4261–4267.

    Article  PubMed  CAS  Google Scholar 

  42. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004, 103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  43. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  44. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096–1102.

    Article  PubMed  CAS  Google Scholar 

  45. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711–4716.

    Article  PubMed  CAS  Google Scholar 

  46. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005, 23:694–704.

    Article  PubMed  CAS  Google Scholar 

  47. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  48. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  49. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin’s lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2005, 23: 1500–1506.

    Article  PubMed  CAS  Google Scholar 

  50. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654–2661.

    Article  PubMed  CAS  Google Scholar 

  51. McLaughlin P, Rodriguez MA, Hagemeister FB, Romaguera J, Sarris AH, Younes A, Dang NH, Goy A, Samaniego F, Hess M. Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 2003, 22:564 (abstract 2269).

    Google Scholar 

  52. Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, Horning SJ. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 2004, 23:556 (abstract 6502).

    Google Scholar 

  53. Van Oers MHJ, Van Glabbeke M, Teodorovic I, Rozewicz C, Klasa R, Marcus RE, Wolf M, Kimby E, Hagenbeek A. Chimeric anti-CD20 monoclonal antibody (rituximab; mabtheraa) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma : a phase III Randomized intergroup clinical trial. Blood 2004, 104:169a (abstract 586).

    Google Scholar 

  54. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927–1932.

    PubMed  CAS  Google Scholar 

  55. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235–242.

    Article  PubMed  CAS  Google Scholar 

  56. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse Large B-Cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005, 23:4117–4126.

    Article  PubMed  CAS  Google Scholar 

  57. Pfreundschuh M, Truemper L, Gill D, Osterborg A, Pettengell R, Trneny M, Imrie K, Walewski J, Zinzani P-L, Loeffler M. First analysis of the completed Mabthera international (Mint) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease. Blood 2004, 104:48a (abstract 157).

    Google Scholar 

  58. Habermann TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 102:(abstract 8).

    Google Scholar 

  59. Habermann TM, Weller E, Morrison VA, Cassileth PA, Cohn J, Dakhil S, Gascoyne RD, Woda B, Fisher R, Peterson BA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL). Blood 2004, 104:(abstract 127).

    Google Scholar 

  60. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705–711.

    Article  PubMed  CAS  Google Scholar 

  61. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984–1992.

    Article  PubMed  CAS  Google Scholar 

  62. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin’s lymphoma: AIDS-malignancies consortium trial 010. Blood 2005.

    Google Scholar 

  63. Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005, 23:247–248.

    Article  PubMed  Google Scholar 

  64. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005, 106:795–802.

    Article  PubMed  CAS  Google Scholar 

  65. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003, 348:2691–2694 (discussion 2691–2694).

    Article  PubMed  Google Scholar 

  66. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Plantier I, Morlat P, Milpied N, Raphael M, Lancar R, Costagliola D. CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma-results of an ANRS trial. Blood 2002, 100:470a (abstract 1824).

    Google Scholar 

  67. Spina M, Tirelli U. HIV-related non-Hodgkin’s lymphoma (HIV-NHL) in the era of highly active antiretroviral therapy (HAART): some still unanswered questions for clinical management. Ann Oncol 2004, 15:993–995.

    Article  PubMed  CAS  Google Scholar 

  68. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005, 105:1891–1897.

    Article  PubMed  CAS  Google Scholar 

  69. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004, 22:1491–1500.

    Article  PubMed  CAS  Google Scholar 

  70. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988, 2:1394–1399.

    Article  PubMed  CAS  Google Scholar 

  71. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993, 293 (Pt 3):633–640.

    PubMed  CAS  Google Scholar 

  72. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35:118–127.

    Article  PubMed  CAS  Google Scholar 

  73. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. J Clin Pathol 1994, 47:313–317.

    Article  PubMed  CAS  Google Scholar 

  74. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989, 73:1431–1439.

    PubMed  CAS  Google Scholar 

  75. Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–3561.

    Article  PubMed  CAS  Google Scholar 

  76. Harris NL, Jaffe ES, Stein H, Vardiman JW (Ed): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.

    Google Scholar 

  77. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998, 92:76–82.

    PubMed  CAS  Google Scholar 

  78. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 1997, 89:4514–4520.

    PubMed  CAS  Google Scholar 

  79. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998, 22:185–191.

    Article  PubMed  CAS  Google Scholar 

  80. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin’s lymphoma. Leuk Lymphoma 2001, 41:77–87.

    Article  PubMed  CAS  Google Scholar 

  81. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin’s lymphomas: a multicenter phase I/II study. Ann Hematol 2002, 81:26–32.

    Article  PubMed  CAS  Google Scholar 

  82. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1998, 16:3257–3263.

    PubMed  CAS  Google Scholar 

  83. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920–2924.

    Article  PubMed  CAS  Google Scholar 

  84. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003, 101:4267–4272.

    Article  PubMed  CAS  Google Scholar 

  85. Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005, 90:702–703.

    PubMed  CAS  Google Scholar 

  86. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10:2253–2264.

    Article  PubMed  CAS  Google Scholar 

  87. Eisenbeis CF, Leonard J, Rosenblatt J, Khan KD, Porcu P, Milan S, Wilson SE, Hurst D, Caligiuri MA, Piro L. Conversion of antibody-resistant cancer patients to antibody-sensitive: investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients. Proc Am Soc Clin Oncol 2004, 22:171 (abstract 2534).

    Google Scholar 

  88. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489–495.

    Article  PubMed  CAS  Google Scholar 

  89. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res 2004, 10:2868–2878.

    Article  PubMed  CAS  Google Scholar 

  90. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793–1800.

    Article  PubMed  CAS  Google Scholar 

  91. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997, 15:481–504.

    Article  PubMed  CAS  Google Scholar 

  92. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003, 21:3051–3059.

    Article  PubMed  CAS  Google Scholar 

  93. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004, 10: 5327–5334.

    Article  PubMed  CAS  Google Scholar 

  94. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004, 10:7792–7798.

    Article  PubMed  CAS  Google Scholar 

  95. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999, 17:3793–3803.

    PubMed  CAS  Google Scholar 

  96. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004, 103: 4429–4431.

    Article  PubMed  CAS  Google Scholar 

  97. Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanouilides C, Cripe L, Saleh M, Czuczman MS, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Semin Oncol 2002, 29:87–92.

    Article  PubMed  CAS  Google Scholar 

  98. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-Lopez A, Chinn P, Varns C, Ning SC, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996, 2:457–470.

    PubMed  CAS  Google Scholar 

  99. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:2453–2463.

    Article  PubMed  CAS  Google Scholar 

  100. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712–719.

    Article  PubMed  CAS  Google Scholar 

  101. Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2004, 22:1469–1479.

    Article  PubMed  CAS  Google Scholar 

  102. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003, 102:1606–1612.

    Article  PubMed  CAS  Google Scholar 

  103. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995, 346:336–340.

    Article  PubMed  CAS  Google Scholar 

  104. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16: 3270–3278.

    PubMed  CAS  Google Scholar 

  105. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol 2005, 23:461–467.

    Article  PubMed  CAS  Google Scholar 

  106. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005, 105:4576–4582.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Richard R. Furman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Leonard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julian Decter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Morton Coleman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology and Toxicology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

    David A. Gewirtz

  2. Departments of Medicine, Pharmacology and Toxicology, Biochemistry and Massey Cancer Center, Virginia Commonwealth, Richmond, VA

    Shawn E. Holt

  3. Departments of Pathology, Human Genetics, Pharmacology and Toxicology, Biochemistry and Massey Cancer Center, Virginia Commonwealth, Richmond, VA

    Steven Grant

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Furman, R.R., Leonard, J.P., Decter, J., Coleman, M. (2007). Monoclonal Antibodies in Lymphomas. In: Gewirtz, D.A., Holt, S.E., Grant, S. (eds) Apoptosis, Senescence, and Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-221-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-221-2_25

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-527-9

  • Online ISBN: 978-1-59745-221-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation